1-5 of 5
Corynn Kasap, BS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,

Catherine C. Smith, MD, Michael Brown, PhD, Jason Chin, PhD, Corynn Kasap, BS, Sara Salerno, BS, Lauren E. Damon, Kevin Travers, PhD, Susana Wang, Andrew Kasarskis, PhD, Eric Schadt, PhD, Neil Shah, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3752.
https://doi.org/10.1182/blood.V118.21.3752.3752
Published: 2011
Journal Articles

Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia

Kathryn G. Roberts, PhD, Ryan D Morin, M.Sc., Jinghui Zhang, PhD, Martin Hirst, Ph.D., Richard C. Harvey, PhD, Corynn Kasap, BS, Xiang Chen, PhD, Michael Edmonson, Ph.D., I-Ming Chen, DVM, MS, Neil Shah, MD, PhD, Meenakshi Devidas, PhD, Gregory H. Reaman, MD, Malcolm A. Smith, MD, PhD, Ching-Hon Pui, MD, James R. Downing, MD, Daniela S Gerhard, Ph.D., Cheryl L Willman, MD, Mignon L Loh, MD, Stephen P Hunger, MD, Marco A. Marra, PhD, Charles G Mullighan, MBBS, MD, FRACP, FRCPA, MSc
Journal: Blood
Blood (2011) 118 (21): 67.
https://doi.org/10.1182/blood.V118.21.67.67
Published: 2011
Journal Articles

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph + + Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

Jorge Cortes, MD, Ronald Paquette, MD, Moshe Talpaz, Javier Pinilla, MD, PhD, Ekatherine Asatiani, MD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, Corynn Kasap, BS, Lynne A. Bui, MD, Douglas O. Clary, PhD, Neil Shah, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3232.
https://doi.org/10.1182/blood.V112.11.3232.3232
Published: 2008
Journal Articles

Beyond the Gatekeeper: Imatinib- and Dasatinib-Resistant BCR-ABL/F317 Mutations Confer Cross-Resistance to VX-680 but Are Sensitive to a Structural Derivative of VX-680

Corynn Kasap, BS, Nicholas Hertz, B.S., Debora Makino, Ph.D., Kevan Shokat, Ph.D., John Kuriyan, Ph.D., Neil P. Shah, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 725.
https://doi.org/10.1182/blood.V112.11.725.725
Published: 2008
Journal Articles

Optimal Treatment for Patients after Dasatinib or Nilotinib: Comparison of Preclinical Activities of Approved and Promising Investigational Kinase Inhibitors Against BCR-ABL Kinase Domain Mutations That Confer Clinical Resistance to Dasatinib or Nilotinib.

Corynn Kasap, BS, Christopher Weier, BS, Neil P. Shah, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 4589.
https://doi.org/10.1182/blood.V110.11.4589.4589
Published: 2007